Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 394

Results For "LA"

8525 News Found

Curium completes acquisition of Monrol
News | March 29, 2025

Curium completes acquisition of Monrol

Positions Curium as leading manufacturer of Lu-177 isotope

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
News | March 29, 2025

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD
News | March 29, 2025

Sanofi & Regeneron’s Dupixent receives Japanese marketing approval to treat patients with COPD

Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)

WeylChem strengthens custom manufacturing with unified leadership
People | March 27, 2025

WeylChem strengthens custom manufacturing with unified leadership

Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
Drug Approval | March 27, 2025

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

Merck inks $200 million deal for Hengrui's midstage heart disease drug
News | March 26, 2025

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

Wipro announces AI Agent Solutions across healthcare industry
Digitisation | March 25, 2025

Wipro announces AI Agent Solutions across healthcare industry

Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda
Healthcare | March 25, 2025

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%

J&J to break ground on new biologics facility in North Carolina
News | March 24, 2025

J&J to break ground on new biologics facility in North Carolina

New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases

Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG
News | March 24, 2025

Marksans Pharma’s manufacturing facility at Verna, Goa approved by Australian TG

The products will be manufactured in Goa India and marketed & distributed in Australian markets

Latest Stories

Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil

Gilead’s new HIV therapy shows promising Phase 3 results

Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging